UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 519

Sortiert nach

Minimizing efficacy differences between phase II and III RCTs

Nature reviews. Rheumatology, 2020-07, Vol.16 (7), p.359-360

Strand, Vibeke

2020

Link zum Volltext

Verfügbarkeit prüfen

Nordic Equality and Anti-Discrimination Laws in the Throes of Change: Legal Developments in Sweden, Finland, Norway, and Iceland

1, 2024

Link zum Volltext

Verfügbarkeit prüfen

Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?

The Lancet (British edition), 2007-12, Vol.370 (9605), p.2138-2151

Strand, Vibeke, Prof

2007

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity of biologic agents in rheumatology

Nature reviews. Rheumatology, 2021-02, Vol.17 (2), p.81-97

2021

Link zum Volltext

Verfügbarkeit prüfen

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?

Rheumatic & musculoskeletal diseases open, 2021-02, Vol.7 (1), p.e001565

Strand, Vibeke

2021

Link zum Volltext

Verfügbarkeit prüfen

Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update

Clinical rheumatology, 2021-08, Vol.40 (8), p.3027-3037

2021

Link zum Volltext

Verfügbarkeit prüfen

Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0

Journal of clinical epidemiology, 2014-07, Vol.67 (7), p.745-753

2014

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2017-08, Vol.31 (4), p.299-316

2017

Link zum Volltext

Verfügbarkeit prüfen

Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years

Lupus, 2021-04, Vol.30 (4), p.578-586

2021

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study

Arthritis research & therapy, 2019-02, Vol.21 (1), p.61-61, Article 61

2019

Link zum Volltext

Verfügbarkeit prüfen

The changing landscape of biosimilars in rheumatology

Annals of the Rheumatic Diseases, 2016-06, Vol.75 (6), p.974-982

2016

Link zum Volltext

Verfügbarkeit prüfen

Interpreting the ECHR in its normative environment: interaction between the ECHR, the UN convention on the elimination of all forms of discrimination against women and the UN convention on the rights of the child

The international journal of human rights, 2020-08, Vol.24 (7), p.979-992

Blaker Strand, Vibeke

2020

Link zum Volltext

Verfügbarkeit prüfen

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group

Journal of rheumatology, 2015-11, Vol.42 (11), p.2168

2015

Link zum Volltext

Verfügbarkeit prüfen

Measuring worker productivity: frameworks and measures

Journal of rheumatology, 2009-09, Vol.36 (9), p.2100

2009

Link zum Volltext

Verfügbarkeit prüfen

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

Arthritis research & therapy, 2019-12, Vol.21 (1), p.263-10, Article 263

2019

Link zum Volltext

Verfügbarkeit prüfen

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

Arthritis research & therapy, 2020-10, Vol.22 (1), p.1-243, Article 243

2020

Link zum Volltext

Verfügbarkeit prüfen

Biologic therapies in rheumatology: lessons learned, future directions

Nature reviews. Drug discovery, 2007-01, Vol.6 (1), p.75-92

2007

Link zum Volltext

Verfügbarkeit prüfen

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

Arthritis research & therapy, 2020-10, Vol.22 (1), p.250-250, Article 250

2020

Link zum Volltext

Verfügbarkeit prüfen

OMERACT: an international initiative to improve outcome measurement in rheumatology

Trials, 2007-11, Vol.8 (1), p.38-38, Article 38

2007

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

Arthritis research & therapy, 2019-02, Vol.21 (1), p.64-64, Article 64

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease

Mayo Clinic proceedings, 2017-04, Vol.92 (4), p.555-564

2017

Link zum Volltext

Verfügbarkeit prüfen

Fibromyalgia syndrome module at OMERACT 9: domain construct

Journal of rheumatology, 2009-10, Vol.36 (10), p.2318

2009

Link zum Volltext

Verfügbarkeit prüfen

The role of biosimilars in the treatment of rheumatic diseases

Annals of the Rheumatic Diseases, 2013-03, Vol.72 (3), p.322-328

2013

Link zum Volltext

Verfügbarkeit prüfen

Updating the core domains set in Systemic Lupus Erythematosus: Work planned by the Systemic Lupus Erythematosus OMERACT working group

Lupus, 2023-04, Vol.32 (4), p.586-588

2023

Link zum Volltext

Verfügbarkeit prüfen

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY

Rheumatology (Oxford, England), 2021-07, Vol.60 (7), p.3209-3221

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 519

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(442)
Mit Volltextzugriff
(370)

Publikationsform

Artikel
(485)
Buchkapitel
(32)
Bücher
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(368)
Life Sciences & Biomedicine
(366)
Rheumatology
(332)
Humans
(331)
Treatment Outcome
(135)
Rheumatoid Arthritis
(133)
Female
(123)
Male
(116)
Biological And Medical Sciences
(111)
Medical Sciences
(110)
Middle Aged
(95)
Arthritis, Rheumatoid - Drug Therapy
(92)
Quality Of Life
(92)
Adult
(85)
Severity Of Illness Index
(84)
Diseases Of The Osteoarticular System
(81)
Antirheumatic Agents - Therapeutic Use
(78)
Clinical Trials
(70)
Patients
(70)
Psoriatic Arthritis
(59)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Minimizing efficacy differences between phase II and III RCTs

Nordic Equality and Anti-Discrimination Laws in the Throes of Change: Legal Developments in Sweden, Finland, Norway, and Iceland

Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?

Immunogenicity of biologic agents in rheumatology

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?

Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update

Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years

Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study

The changing landscape of biosimilars in rheumatology

Interpreting the ECHR in its normative environment: interaction between the ECHR, the UN convention on the elimination of all forms of discrimination against women and the UN convention on the rights of the child

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group

Measuring worker productivity: frameworks and measures

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

Biologic therapies in rheumatology: lessons learned, future directions

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab

OMERACT: an international initiative to improve outcome measurement in rheumatology

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial

Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease

Fibromyalgia syndrome module at OMERACT 9: domain construct

The role of biosimilars in the treatment of rheumatic diseases

Updating the core domains set in Systemic Lupus Erythematosus: Work planned by the Systemic Lupus Erythematosus OMERACT working group

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY

Suchergebnisse filtern